| ASSET | YEAR | % RETURN |
|---|---|---|
Crispr Therapeutics (CRSP) | 2016 | 35.07% |
Crispr Therapeutics (CRSP) | 2017 | 11.81% |
Crispr Therapeutics (CRSP) | 2018 | 19.04% |
Crispr Therapeutics (CRSP) | 2019 | 118.77% |
Crispr Therapeutics (CRSP) | 2020 | 152.28% |
Crispr Therapeutics (CRSP) | 2021 | -51.98% |
Crispr Therapeutics (CRSP) | 2022 | -46.91% |
Crispr Therapeutics (CRSP) | 2023 | 51.98% |
Crispr Therapeutics (CRSP) | 2024 | -36.35% |
Crispr Therapeutics (CRSP) | 2025 | 44.66% |
